ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care

Oct 23 2023

• By Kevin Grogan

Listen to this article

The combination of Astellas and Seagen's antibody-drug conjugate Padcev and Merck & Co's checkpoint inhibitor Keytruda has shown improvements in survival not previously achieved in a broad population of patients with advanced urothelial carcinoma.

ESMO 23 queue — • Source: ESMO

Delegates at the European Society for Medical Oncology meeting in Madrid were delighted to see two Phase III trials for the first-line treatment of urothelial carcinoma (UC) read out with positive overall survival results but the one that had the audience on their feet hailing a new standard of care was the combination of Seagen Inc. and Astellas Pharma, Inc.'s Padcev and Merck & Co., Inc.'s Keytruda.

Positive topline data from the Phase III EV-302/KEYNOTE-A39 trial were reported last month from the study looking at the combination...

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Dec 05 2025
• By Xu Hu
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer
Sep 24 2025
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.